08/28/2026
New research suggests the economics of GLP-1s may not conform to a popular, bleak, and possibly false narrative that depicts obesity medicines as a money pit. To the contrary, with persistent use, they may save money.
HT: Eli Lilly and Company
https://conscienhealth.org/2026/08/28/might-cost-savings-pay-for-the-glp-1-bridge-program/